|
(SC6)
CIRCULATING TUMOR CELLS
Moderator:
Minetta C. Liu, M.D., Assistant Professor of Medicine and
Oncology, Lombardi Comprehensive Cancer Center, Georgetown
University Hospital
Insights
into the Biology of Circulating Tumor Cells
John W. Park, M.D., Associate Professor, Medicine,
University of California, San Francisco
Circulating
Tumor Cell Applications in the Pre-Clinical Phase of Drug
Development
Gerald V. Doyle, DDS, MS, Senior Director, Clinical
Research, Immunicon Corp.
CTCs:
A Reliable Assessment of Treatment Efficacy in Metastatic
Breast Cancer
Minetta C. Liu, M.D., Assistant Professor of
Medicine and Oncology, Lombardi Comprehensive Cancer
Center, Georgetown University Hospital
Clinical
Utility of CTCs for Prostate Cancer
Howard I. Scher, M.D., D. Wayne Calloway Chair in
Urologic Oncology, Chief, Genitourinary Oncology Service,
Department of Medicine, Sidney Kimmel Center for Prostate
and Urologic Cancers, Memorial Sloan-Kettering Cancer
Center
(SC7) CANCER STEM CELLS
Chairperson:
Craig T. Jordan, Ph.D., Director, Hematologic
Malignancies Translational Research Program, James P.
Wilmot Cancer Center and Associate Professor of Medicine,
University of Rochester School of Medicine
-
Techniques
for isolating cancer stem cells
-
Methods
to characterize cancer stem cells
-
Approaches
for developing anti-cancer stem cells compounds
2:30
Characterization and Targeting of Leukemia Stem Cells
Craig T. Jordan
Malignant stem cells have recently emerged as a major
factor in the genesis and perpetuation of several types of
cancer. This phenomenon is particularly well characterized
for the blood cancer leukemia. This presentation will
provide a general overview of leukemia stem cell biology
with a particular emphasis on features relevant to
therapy. Strategies for selective targeting of leukemia
stem cells will be discussed and future
objectives/directions will be proposed.
3:05
“Cancer Stem Cells” in solid epithelial tumors:
working definition and implications for patient prognosis
Piero Dalerba, Ph.D., Stanford Institute for Stem Cell
Biology and Regenerative Medicine, Stanford University
A growing body of evidence is increasingly lending support
to the concept that cancer can be studied and modeled as a
stem-cell disease. This hypothesis is supported by the
observation that only a phenotypic subset of cancer cells,
usually termed “cancer stem cells” (CSC), is capable
of initiating tumor growth when transplanted into
immunodeficient mice. Research in our laboratory focuses
on the study of human CSC in solid epithelial tumors and
recently led to two major advancements: 1) we were able to
extend the CSC model to the study of human colorectal
cancer, developing a very robust protocol for isolation of
human colorectal CSC (Co-CSC), based on a novel set of
three independent surface markers (EpCAM/CD44/CD166); 2)
by analysis of the gene-expression profile of human
“breast cancer stem cells” (Br-CSC), we were able to
identify a gene-expression signature that could be used to
stratify breast cancer patients into different prognostic
categories, thus providing the first evidence of the
potential clinical implications of human CSC isolation.
3:40
Break
3:55
Identification of Stem Like Cells in Bone Sarcomas
Dr. C. Parker Gibbs, Associate Professor, Orthopaedics,
University of Florida
Cancer stem cells have been implicated in the pathogenesis
of several malignancies including leukemia and epithelial
cancers. However, their role in mesenchymal solid tumors
is much less understood. This presentation will focus on
the identification and role of cells in bone sarcomas that
appear to utilize the machinery of mesenchymal and
embryonic stem cells to facilitate their malignant
potential. Possible therapeutic intervention relative to
this concept will be discussed.
4:30
Characterizing Brain Tumor Stem Cells in Man and Mouse
Peter B. Dirks, Ph.D., Scientist & Principal
Investigator, Neurosurgery, Hospital for Sick Children
Brain tumors, in humans and in some mouse models, are
organized as a functional hierarchy with growth dependent
on relatively rare cells that have stem cell properties.
These brain tumor stem cells can be prospectively enriched
by sorting for cell surface markers. Recently, we have
used chemical biological screens to identify agents that
suppress normal and brain tumor stem cell proliferation.
These agents reveal
possible new drugs for human brain tumors and also suggest
additional pathways that may regulate neural stem cells.
5:00
Panel Discussion: Is there Proof of Cancer Stem Cells in
all Cancers?
(SC8) Models for Evaluating Drug-Drug Interaction Potential in PreClinical Development
Joseph Ware, Ph.D., Senior. Scientist, Late Stage PK/PD, Genentech, Inc.
James McKim, Ph.D., DABT, President & Chief Scientific Officer, CeeTox, Inc.
Philip S. Burton, Ph.D., Chief Executive & Scientific Officer, ADMETRx, Inc.
This course will cover:
-
An overview of drug-drug interactions from the clinical perspective, withdrawn drugs and the overall impact on development
-
CYP inhibition and induction methods and in vitro/ in vivo correlations
-
Transporter models and in vitro/in vivo correlations
(SC10) BEST PRACTICES FOR COMPILING A REGULATORY DOSSIER FOR
REGULATORY BODIES IN INDIA: A HANDS-ON WORKSHOP
Brijesh Regal, C.E.O., Apothecaries Clinical Research, New Delhi, India
(Former WHO Consultant to Drugs Controller General of India,
and coordinated the development of Schedule Y)
-
In-depth understanding of regulations
in general, and Schedule Y in particular, that prescribe
documents for regulatory dossiers
-
Inventory and depth level of documents
that need to go into the regulatory dossiers for various phases
of clinical trials or for
products registrations
-
Prescribed ICDs for clinical trials
-
Preparing documents to be submitted to
ethics committees
-
Import and export regulations for
clinical trial material
|
